A Phase 2 interventional study of Monalizumab (anti-NKG2A monoclonal antibody) in Acute Myeloid Leukaemia, MDS (Myelodysplastic Syndrome) and MPN (Myeloproliferative Neoplasms), sponsored by Istituto Clinico Humanitas. Recruiting at 2 sites in Italy. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Istituto Clinico Humanitas · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 229 studies in Leukemia, Myeloid, Acute with a site in Italy — 45 open to participants now, 68 under way, 16 of them phase 3. Leukemia, Myeloid, Acute · Italy.
Among the 229 studies in Leukemia, Myeloid, Acute with a site in Italy, this one is the 156th largest by planned enrollment of the 196 interventional ones that give a count, is one of 16 that started in 2021, is one of 52 in phase 2, reaches primary completion later than 10 of the 67 other live ones, and was the 212th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →45 of the 229 studies in Leukemia, Myeloid, Acute with a site in Italy are open now. Recruiting first, the newest first:
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18–75 · Healthy volunteers
Fondazione Matilde Tettamanti Menotti De Marchi Onlus · Sites in Italy
Ages 6 mo–75 yrs
Gruppo Italiano Malattie EMatologiche dell'Adulto · Sites in Italy
Ages 18+
AbbVie · Sites in Italy, United States, Australia and 4 more countries
Ages 6 mo–17 yrs
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · Sites in Italy
Ages 18–75
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
229 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 68 · Phase 2 100 · Phase 3 62 · Phase 4 1
First in 1993; this study’s year is marked. 16 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is close to the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 120 across the 196 interventional studies, 202 across the 31 observational. Of the 139 that completed or were terminated, 76 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
130 of 229 have an industry lead sponsor. The 10 most frequent:
Istituto Clinico Humanitas is the lead sponsor of 279 studies on the registry; 70 are open to participants now.
Istituto Clinico Humanitas has 2 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
14 of the studies in Leukemia, Myeloid, Acute with a site in Italy that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05183035Phase 3PedAL BCU, LLCVenetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | 2027-02 |
| NCT05429632Phase 3Priothera SASMocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | 2027-05 |
| NCT05907057Phase 3Servier Affaires MédicalesAn Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | 2027-10-15 |
| NCT04256317Phase 3Taiho Oncology, Inc.A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | 2027-11-01 |
| NCT04232241Universitätsklinikum Hamburg-EppendorfMatched Unrelated vs. Haploidentical Donor for Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | 2026-11-22 |
Add all 14 to your calendar (.ics) → With an account.
Among the 229 studies in Leukemia, Myeloid, Acute with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to evaluate the effectiveness and safety of the anti-NKG2A monoclonal antibody (Monalizumab) in patients undergoing haploidentical stem cell transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy). The main questions this trial aims to answer are:
Participants will:
This Phase II non-randomized, open-label, single-arm, monocentric clinical trial aims to evaluate the safety, efficacy, and biological impact of Monalizumab (humZ270 mAb, IPH2201), an anti-NKG2A monoclonal antibody, in patients undergoing haploidentical stem cell transplantation (Haplo-SCT) with post-transplantation cyclophosphamide (PT-Cy). The study is designed to investigate how the optimization of the dose of this novel antibody can improve the graft-versus-host disease (GVHD)-free and progression-free survival (GPFS) in patients with hematological malignancies, specifically Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).
Background and Rationale:
Haploidentical stem cell transplantation with PT-Cy as GVHD prophylaxis is a widely used option for patients requiring allogeneic transplantation. However, relapse and GVHD remain significant issues, leading to a GPFS of approximately 30-40%. Alloreactive natural killer (NK) cells play a critical role in graft-versus-tumor (GVT) effects, anti-GVHD, and anti-infectious responses. CD94/NKG2A+ NK cells are prominent early post-transplant, but their effectiveness can be limited. By using anti-NKG2A antibody, NK cell alloreactivity can be enhanced, circumventing the need for an NK alloreactive donor. Preclinical studies have demonstrated that anti-NKG2A antibody treatment restores NK cell-mediated lysis of AML cells, both in vitro and in vivo. This trial aims to assess the clinical benefits of optimizing the dose of anti-NKG2A monoclonal antibody in the Haplo-SCT setting.
Monalizumab is a first-in-class humanized IgG4 antibody targeting the NKG2A receptor on NK cells. It has previously been tested in Phase I trials in solid tumors with promising results at a dosage of 10 mg/kg. In this study, the aim is to optimize the dosage for patients undergoing Haplo-SCT.
Study Design:
This is a non-profit, prospective, open-label, single-arm, monocentric study. The study duration is 5 years, during which participants will receive Monalizumab intravenously at a dose of 1 mg/kg on days +30 and +44 after transplantation. Day +30 is chosen as the starting point for antibody administration as CD94/NKG2A+ NK cells predominate at this time post-transplantation. Additionally, the half-life of Monalizumab is 21 days, meaning two infusions will cover the entire period of NK cell expansion.
The study aims to determine whether the administration of Monalizumab at this timepoint can enhance NK cell alloreactivity and reduce the incidence of GVHD and relapse. The treatment will be stopped if at least three patients develop grade 3-4 acute GVHD after receiving Monalizumab or if any severe adverse events (SAEs) occur that warrant stopping the infusion.
Treatment Plan:
Eligible participants will receive Monalizumab at 1 mg/kg intravenously on days +30 and +44 after undergoing Haplo-SCT. The treatment will be administered as part of the standard care for patients undergoing Haplo-SCT with PT-Cy prophylaxis, which includes Cyclophosphamide (40-50 mg/kg/day on days +3 and +4), Cyclosporine A (3 mg/kg/day starting from day +5), and Mycophenolate Mofetil (45 mg/kg/day from day +5 to day +35).
Primary Objective:
The primary objective of this study is to evaluate the efficacy and safety of Monalizumab in patients undergoing Haplo-SCT with PT-Cy. The primary endpoint is the graft-versus-host disease-free and progression-free survival (GPFS) at one year post-transplantation. This measure will help determine whether Monalizumab improves the overall outcome of patients receiving Haplo-SCT.
Secondary Objectives:
The secondary objectives of this study are:
To evaluate the effect of Monalizumab on the immunological reconstitution of NK cells and other immune cells.
To assess the clinical parameters of survival, toxicity, and the incidence of complications such as relapse, GVHD (both acute and chronic), and post-transplant viral infections.
Endpoints:
Primary Endpoint: The GPFS at 1 year after Haplo-SCT.
Secondary Endpoints:
Clinical Endpoints: Incidence of overall survival (OS), progression-free survival (PFS), non-relapse mortality (NRM), and post-transplant viral infections (including Cytomegalovirus).
Biological Endpoints: Evaluation of NK cell reconstitution and alloreactive functions against leukemic cells following administration of Monalizumab.
Statistical Analysis:
A detailed statistical analysis plan will be followed to address the primary and secondary objectives. Statistical techniques such as Kaplan-Meier analysis will be used to assess survival outcomes, while Cox proportional hazards models will help evaluate the effect of Monalizumab on various clinical and biological parameters. The analysis will include data from all evaluable patients and will be conducted at predefined time points, primarily focusing on the one-year follow-up.
Patient Population:
This study will include adult patients (≥18 years old) with hematologic malignancies, including AML, MDS, and MDS/MPN, who are undergoing Haplo-SCT with PT-Cy. The inclusion criteria are as follows:
Patients capable of providing informed consent and willing to comply with study procedures.
Patients with no HLA-matched donor but who are receiving Haplo-SCT with GVHD prophylaxis.
Patients must have received a myeloablative, reduced intensity, or non-myeloblative conditioning regimen, followed by a bone marrow or peripheral blood stem cell (PBSC) graft.
Women of childbearing potential must use effective contraception during the study.
Safety and Monitoring:
The study will include continuous monitoring for adverse events (AEs) and serious adverse events (SAEs). The occurrence of grade 3-4 acute GVHD following Monalizumab administration will trigger the suspension of the treatment. Regular laboratory tests, physical exams, and imaging (if applicable) will be performed throughout the study to assess the health status of participants. A Data Safety Monitoring Board (DSMB) will oversee the trial to ensure patient safety.
Quality Assurance Plan:
The study will adhere to high standards for data validation and monitoring. Data will be regularly checked for consistency and accuracy against predefined rules. Source data verification will be carried out to ensure that data entered into the study database is complete and accurate. The study will also follow strict SOPs to ensure proper data collection, management, and analysis. Audits will be conducted periodically to ensure compliance with the protocol and regulatory requirements.
Sample Size and Statistical Power:
The sample size for this study has been calculated to provide adequate statistical power (90%) to detect a meaningful difference in GPFS. The goal is to enroll approximately 18 evaluable patients, with a planned interim analysis after the first few patients have completed one year of follow-up.
Plan for Missing Data:
Missing data will be handled using standard statistical techniques such as imputation for missing values, and sensitivity analyses will be performed to account for missing data in the analysis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study includes a single arm, where all patients will receive Monalizumab (humZ270 mAb, IPH2201), an anti-NKG2A monoclonal antibody, as the intervention. Monalizumab is administered intravenously at a dose of 1 mg/kg on day +30 and day +44 after undergoing haploidentical stem cell transplantation (Haplo-SCT). The use of post-transplantation cyclophosphamide (PT-Cy) is part of the conditioning regimen and inclusion criteria but is not part of the protocol-specified intervention. Monalizumab aims to enhance the immune function of NK cells by blocking the NKG2A receptor, potentially improving graft-versus-host disease (GVHD)-free and progression-free survival (GPFS).
Drug: Monalizumab (anti-NKG2A monoclonal antibody)
Monalizumab (humZ270 mAb, IPH2201) is a humanized IgG4 monoclonal antibody targeting the NKG2A receptor on NK cells. Administered intravenously at a dose of 1 mg/kg on days +30 and +44 after haploidentical stem cell transplantation with post-transplant cyclophosphamide (PT-Cy) as GVHD prophylaxis, Monalizumab aims to enhance NK cell activity by blocking NKG2A. This intervention is unique in its timing, as it is given during a period when CD94/NKG2A+ NK cells are abundant, and its two-dose regimen is designed to optimize NK cell reconstitution. It targets patients with hematologic malignancies, such as AML and MDS, to improve GVHD-free and progression-free survival by enhancing NK cell-mediated immunity. This approach differs from other therapies by focusing on NK cell alloreactivity in the post-transplant setting. Cyclophosphamide is used as part of the pre-transplant conditioning regimen and is part of the inclusion criteria, but it is not part of the protocol-specific intervention.
Also known as: humZ270, mAb IPH2201
Graft-versus-host disease-free and progression-free survival (GPFS)
GPFS is defined as the time from Haplo-SCT with post-transplant cyclophosphamide (PT-Cy) until the occurrence of either graft-versus-host disease (GVHD) or disease progression/relapse. This measure evaluates the combined effect of Monalizumab (NKG2A blockade) in preventing both GVHD and disease progression. It is a comprehensive indicator of treatment efficacy, assessing whether the addition of Monalizumab improves patient outcomes by prolonging the period free of both GVHD and disease progression.
Time frame: GPFS will be evaluated 1 year after Haplo-SCT with PT-Cy and Monalizumab administration on day +30 and +44.
Overall Survival (OS)
Overall Survival (OS) is defined as the time from Haplo-SCT with post-transplant cyclophosphamide (PT-Cy) and Monalizumab administration until death from any cause. It is a key indicator of the overall benefit of the treatment, evaluating whether the addition of Monalizumab improves long-term survival in patients undergoing Haplo-SCT.
Time frame: Overall Survival (OS) will be evaluated at 1 year after Haplo-SCT
Progression-Free Survival (PFS)
Progression-Free Survival (PFS) is defined as the time from Haplo-SCT with post-transplant cyclophosphamide (PT-Cy) and Monalizumab administration until the occurrence of disease progression or relapse. PFS evaluates the efficacy of Monalizumab in delaying or preventing the progression of hematological malignancies, such as Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), after Haplo-SCT.
Time frame: PFS will be evaluated at 1 year after Haplo-SCT
Non-Relapse Mortality (NRM)
Non-Relapse Mortality (NRM) refers to mortality from causes other than disease relapse or progression, such as complications due to GVHD, infections, or other treatment-related toxicities. NRM will evaluate whether Monalizumab affects the risk of death from non-disease related causes in patients post-Haplo-SCT.
Time frame: NRM will be evaluated at 1 year after Haplo-SCT
Incidence of Acute and Chronic GVHD
This measure tracks the incidence of acute and chronic GVHD in patients after Haplo-SCT with PT-Cy and Monalizumab treatment. It evaluates whether the addition of Monalizumab affects the rate of GVHD development.
Time frame: GVHD incidence will be assessed at 6 months and 1 year after Haplo-SCT
Post-transplant Viral Infections
The incidence of viral infections (such as CMV, EBV, etc.) will be monitored in patients after Haplo-SCT. This measure will evaluate whether Monalizumab influences the incidence of viral infections post-transplant.
Time frame: Post-transplant viral infections will be assessed until 100 days after Haplo-SCT
Plan to share: No
No publications or documents are linked to this record.
Ran from Dec 2021 to primary completion in Mar 2025, 38 months.
Of 386 non-industry phase 2 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's 38 months is below that.
Counting every sponsor, half of 443 studies reached it within 60 months; a quarter within 38 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Monalizumab